Skip to main content
. 2022 Nov 15;6(12):e807. doi: 10.1097/HS9.0000000000000807

Figure 2.

Figure 2.

Overall survival and progression-free survival according to chemotherapy type. (A) Overall survival and (B) progression-free survival according to the chemotherapy type (G-CHOP and G-Bendamustine) in patients younger than 65 years. (C) Overall survival and (D) progression-free survival according to the chemotherapy type (G-CHOP and G-Bendamustine) in patients older than 65 years. CHOP = CVP + doxorubicine.